Transcript moodle.univ

Khadra LASWAD,
Youssou NDAO,
Anne-Félice PELLET,
Laure TIQUET,
Florent ZOONEKYND
1
Profile
This is an independent study
performed by students from the
Faculté des Sciences
Pharmaceutiques de Lille
The opinions expressed are our
own and not necessarily those of
Eisai
2
Profile
A japanese pharmaceutical company
Created on December 6, 1941
15,000 employees work in America,
Europe and Asia
3
Profile
Manufacturing and marketing of
pharmaceutical drugs, over-thecounter drugs, generic
medicines and veterinary
medicinal products.
Sales in 2011 : 6.42 billions €
R&D : 19,3% of net sales
Total equity : 4,19 billions € (as of
March 31, 2012)
4
History
1941
1981
Nihon Eisai Co., Ltd.
established in Honjomachi, Saitama
Prefecture
Eisai established in
California, United
States.
1961
Eisai listed on the first
section of the Tokyo
and Osaka Stock
Exchanges.
Office established in
Taiwan.
http://eisai.com/company/profile/timeline.html
5
History
1988
Eisai established
in London,
United Kingdom
and in New
Jersey, USA.
1991
Eisai established
in China
1989
1996
Eisai established
in Germany and
Thailand
Eisai established
in France
6
http://eisai.com/company/profile/timeline.html
History
1997
2010
ARICEPT
launched in
the United
States, the
United
Kingdom
and
Germany
ARICEPT
composition
of matter
patent
expires in
the United
States
2007
Acquisition
of
Morphotek
2007
Eisai
established
in India
2008
Acquisition of
MGI
PHARMA,
INC.
7
http://eisai.com/company/profile/timeline.html
Eisai’s Acquisitions : Rich oncology pipeline
2007 : Acquires
Morphotek US
biopharmaceutical
compagny
2008 : Acquires U.S.
biopharmaceutical
company MGI
PHARMA, INC.
Discovery and development of
monoclonal antibodies (mABs)
Chemotherapy Support
8
Eisai Regions
9
Corporate Objectives
Making meaningful contribution under health care system
while observing the highest standards in business activities :
• Improving Access to medicines worldwide
• Providing Products at an Affordable Price
Transformation into a high-performing company by acheving :
• Over 7,9 billion € in net sales
• Over 2 billion € in operating income
• Over 25% operating income ratio by the year
ending 31 March, 2016
10
Strategies
Loss of exclusivity of Aricept®
(Annual Net Sales > 3 b€)
East Japan
Earthquake
Strategies to overcome that situation :
Innovation : New Products Development
Maintaining profitability through sustainable growth in domestic business,
combined with reductions in selling, expenses
Realize interaction of global and regional knowledge (expansion into New
Markets)
Strike a balance among investing for gross future and paying dividend and
debt
11
Eisai products
12
Aricept® Donepezil HCl
Major product
For the treatment of all stages of Alzheimer’s disease – mild,
moderate and severe dementia of the Alzheimer’s type
13
Aricept® Donepezil HCl
Reversible and specific
inhibitor of the
acetylcholinesterase
Loss of ACh caused by the
death of cholinergic
neurons
ACh is involved in memory
and learning
14
Neuroscience area
Research continue since the launch of Aricept :
- adding indications
- more patients
- new formulations
15
http://www.eisai.com/ir/individual/digest/point2_1.html
Neuroscience area
Insomnia treatment :
Lunesta / Eszopiclone
R&D on potential nextgeneration Alzheimer’s
disease drugs
Epilepsy treatments :
Zonegran / Zonisamide
Inovelon / Rufinamide
Zebinix / Eslicabazepine
acetate
Perampanel (on
developing)
16
http://www.eisai.com/ir/individual/digest/point2_1.html
Banzel® / Inovelon® Rufinamide
For adjunctive treatment of
seizures associated with LennoxGastaut syndrome (LGS) in
children 4 years and older and
adults.
LGS is a rare form of epilepsy in
which patients experience seizures
of multiple types. LGS accounts for
1 to 4 percent of all childhood
epilepsy cases.
17
Banzel® / Inovelon® Rufinamide
Tools and Resources
The mechanism of
action is unknown.
http://www.banzel.com/tools-and-resources.aspx
It is presumed to
involve stabilization
of the sodium
channel inactive
state, effectively
keeping these ion
channel closed.
18
Aciphex®/Pariet® Rabeprazole sodium
Aciphex is a proton pump inhibitor
that reduces the amount of acid in
your stomach.
Approved by FDA in 1999
• To heal acid-related damage to the lining of the esophagus
(erosive esophagitis); to relieve symptoms, such as heatburn
pain.
• To maintain the healing of the oesophagus and relif of
symptoms related to erosive esophagitis
• For the treatment of daytime and nightime heartburn and
other symptoms that happen with Gastroesophageal Reflux
Disease.
20
• For the healing and relief of duodenal ulcers
Aciphex®/Pariet® Rabeprazole sodium
Aciphex : Prodrug
Absorption in the small intestine
Systemic blood circulation
Passage through the gastric parietal cell
Reaction with H+ of the parietal cell (HCl) : cyclisation of the molecule
Formation of cyclic sulfenamide : active forme
Irreversible covalent bond with the proton pomp (ATPase H+/K+)
at the SH groups of cysteines
Decrases in the release of H+  increased pH
21
Oncology area
1986 : Start research for
treatments against cancer
Halaven / Eribulin for
breast cancer
E7080 / Lenvatinib VEGF
receptor tyrosine kinase
Eisai is working on developing
multiple anticancer
treatments :
Therapeutic antibodies
MORABb-003 / Farletuzumab
22
http://www.eisai.com/ir/individual/digest/point2_1.html
Consumer health care products
Nabolin
Chocola BB
Juvelux
Selbelle
23
http://www.eisai.com/ir/individual/digest/point1_1.htm
Eisai’s Alliance / Acquisitions History in the US
1994 : Agreement
with Pfizer Inc to copromote Aricept®
1997 : Agreement
with Janssen
Pharmaceuticals Inc to
co-promote Aciphex®
2002 : Acquires
Cerebyx from Warner
Lambert compagny
24
Eisai’s Alliance / Acquisitions History in the US
2003 : Agreement
with Teva
Pharmaceuticals to copromote Rasagiline
2004 : Acquires antiepileptic drug
Zonegran® from Elan
Corporation
25
Eisai’s Alliance / Acquisitions History in the US
2006 : Acquires four
oncology-related
products from Ligand
Pharmaceuticals
ONTAK® (denileukin diftitox)
Exclusive global rights :
TARGRETIN® (bexarotene)
Caspules & Gel 1%
PANRETIN® (alitretinoin) gel 0.1%.
26
Therapeutic areas
27
http://www.eisai.com/ir/individual/digest/point2_1.html
Products supplied in 2009
Aricept €3.20 billion
32%
40%
Total sales
€7.95 billion
Pariet €1.47 billion
Oncology-related
products €0.79 billion
Other products €2.50
billion
10%
18%
28
http://www.eisai.com/pdf/esocial/epdf2010es.pdf
Aricept loss of exclusivity strategy
2010
2011
2012
LOE in US (mild to LOE in EU & Japan
moderate AD) (mild to moderate AD)
2013
LOE of AcipHex in
US
LOE of Pariet in
Europe
29
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Aricept loss of exclusivity strategy
New indications and formulations
New higher dose : Aricept 23 mg tablet
=> launched in August 2010 in the US
=> 2014 in Japan
Weekly transdermal patch formulation => On evaluation
Pediatric indication in US and Europe => On evaluation
30
http://www.eisai.com/news/news200924.html : Current Status of the Development Programs of New Indications and Formulations of Aricept® for Enhancing Patient Value
Products supplied by EISAI
Sales
(billion €)
7.95
7.61
8.00
6.42
7.00
Other products
5.00
Oncology-related
products
Humira
4.00
Pariet
6.00
3.00
Aricept
2.00
1.00
0.00
2009
http://www.eisai.com/pdf/esocial/epdf2012es.pdf
2010
2011
31
Mid term strategic Plan « Hayabusa »
ERA OF
TRANSFORMATION
32
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Roadmap for the Plan « Hayabusa »
Embarked on from April 2011
7,61 b€
1,15 b€
33
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Roadmap for the Plan « Hayabusa »
Embarked on from April 2011
Increase Net Sales
OP margin at 25%
Aim for 7.9 b€ +
7,61 b€
2.0 b€ +
1,15 b€
34
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Global Access
Number of countries
Served by EISAI products
5-year cumulative number of
patients served by EISAI Products
(Million)
114
120
2
10
100
12
13
80
60
66
2
10
37
6
3
40
500+
North America
Central / South
America
Africa
Europe
23
40
20
Middle East
200+
Asia / Oceania
22
0
FY2006-10
FY2011-15
FY2006-10
FY2011-15
(Internal estimates)
35
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Human Health Care
36
Annual report 2012
Human Health Care
Affordability
Providing medicines at affordable prices suitable to the social,
economic and healthcare environments of individual countries.
INDIA :
Aricept® remains the leading
brand.
Price : 90 % less than in Japon.
Free pamphlets and provides
training and education for the
medical staff.
PHILIPPINES :
INDONESIA :
Affordable pricing to Revovir® The price of Aricept® was
(Clevudine) for chronic
revised.
hepatits B.
Sales x4 in 2 years.
Exclusive rights to develop, Support program to raise local
market and manufacture
awareness and improve
compliance.
37
Annual report 2012
Human Health Care
Availability
The Group utilizes the Eisai Knowledge Centre / Vizag Plant in India
strategically to supply high-quality medicines at competitive prices.
30 tons of API - 2 billion tablets per year
Manufacturing and supplying API for products
in emerging and developing countries.
API process research for the next generation
of Eisai’s global products
38
Annual report 2012
Human Health Care
Availability
Development of a New Drug for Chagas Disease
License agreement with the non-profit independent foundation,
Drugs for Neglected Diseases initiative (DNDi)
DNDi
Responsible for
assessment
Eisai
Scientific expertise
Supply drug for the
clinical studies
Manufacture, register
and make available the
product
39
Annual report 2012
Human Health Care
Adoption
Support for the Program to Eliminate Lymphatic Filariasis
International public-private partnership with the aim of investing long term
to bring a “zero price” model for providing medicine to reality.
Eisai : 2.2 billion tablets of
diethylcarbamazine free of charge
through 2020.
40
Annual report 2012
Global Access
Number of countries
Served by EISAI products
5-year cumulative number of
patients served by EISAI Products
(Million)
114
120
2
10
100
12
13
80
60
66
2
10
37
6
3
40
500+
North America
Central / South
America
Africa
Europe
23
40
20
Middle East
200+
Asia / Oceania
22
0
FY2006-10
FY2011-15
FY2006-10
FY2011-15
(Internal estimates)
41
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Entries to all top 20 countries in next 5 years
42
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Make use of significant growth opportunity in
pharmamerging
China
CAGR* = 22.4%
* Compound Annual Growth Rate
•
• Announced the direction of healthcare
reform including shift to provide national
insurance coverage by 2020 (Apr. 2009)
• Revision of National Reimbursement Drug
List (Nov.2009)
New government to enhance access to
medicine and pharmaceuticals (30% increase
in government health care spending)
Brazil
CAGR* = 10.5%
* Compound Annual Growth Rate
India
CAGR* = 14.8%
• Prime Minister sets up expert committee to
propose action for universal health
coverage in India (Oct.2010)
* Compound Annual Growth Rate
43
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Revenue announcement
Revenue by Region
(Billion €)
9
8
7
7%
6%
23%
6
5
4
Others
Europe
40%
4%
1%
US
Emerging
/ New
Mkts
3
East Asia
63%
2
(China CAGR 26%)
49%
1
0
2010
2011
2012
2013
2014
2015
44
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Roadmap for the Plan « Hayabusa »
Global Access
Increase Net Sales
Aim for 7.9 b€ +
7,61 b€
2.0 b€ +
1,15 b€
OP margin at 25%
?
45
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Roadmap for the Plan « Hayabusa »
Structural
transformation
Increase Net Sales
Aim for 7.9 b€ +
7,61 b€
2.0 b€ +
1,15 b€
OP margin at 25%
?
46
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Structural Transformation
5 Regions
47
Environmental_and_social_report_2010, EISAI
Structural Transformation
The Americas
(North, Central and South America)
• Effective and efficient sharing of business resources (knowledge
and experience) developed in the U.S. with Canada and Latin
America
• Utilization of U.S. CPP (Certificate of Pharmaceutical Product)
for regulatory submissions in Latin American countries
• Mexico functions as a major hub of other Spanishspeaking Latin
American countries
CAGR (fiscal 2011 to fiscal 2015) : 7%
48
EISAI annual report 2012
Structural Transformation
5 Regions
49
Environmental_and_social_report_2010, EISAI
Structural Transformation
EMEA
(Europe/the Middle East/Africa)
CAGR (fiscal 2011 to
fiscal 2015) : 5%
• Transmission of medical and marketing knowledge
• Utilize the EU regulatory dossier for regulatory submissions
among countries in the EMEA region
Indo-Pacific
(South Asia, ASEAN countries, and Oceania)
CAGR (fiscal 2011 to
fiscal 2015) : 11%
• Interactive knowledge sharing in the IndoPacific region
• Introduce a range of brand name prescription pharmaceuticals
and branded generics.
50
EISAI annual report 2012 & plan Hayabuza
Structural Transformation
5 Regions
51
Environmental_and_social_report_2010, EISAI
Ressource Optimization
Launch of Eisai East Asia
Japan
Korea
Taiwan
China
Hong Kong
• Implementation of exchange programs involving front-line
sales staff and exchange programs for physicians in the region
• Promotion of mutual understanding through the interaction
of key opinion leaders in Japan and China
• Outward transmission of hhc knowledge accumulated in
Japan to the region
52
EISAI annual report 2012
Ressource Optimization
Launch of Eisai East Asia
Japan
Korea
Taiwan
China
Hong Kong
Major growth driver for the Eisai Group
CAGR (fiscal 2011 to fiscal 2015) : 11%
53
EISAI annual report 2012
Structural optimization
4 Regions
Extension
Regroupment
Interactive knowledge sharing
54
EISAI annual report 2012
Headcounts Reduction
3b€
United States
2010
1.8b€
2015
Transform from mass market/co-promotion model
to independent neuroscience/oncology franchise model
• Focus on women’s oncology, or the treatment of cancers
that primarily affect women, and accelerate the
transformation of this therapeutic franchise
• Further enrich neuroscience franchise with addition of
epilepsy product line
Headcounts from under 1,600 to 1,000+
EISAI annual report 2012 & plan HAYABUZA
55
Roadmap for the Plan « Hayabusa »
New Princeps
Increase Net Sales
Aim for 7.9 b€ +
?
7,61 b€
1,15 b€
OP margin at 25%
56
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Optimization of R&D
Product Creation Units
(PCUs) 6 Discovery Area
Core Function Units (CFUs)
6 Technology & Function Area
Pharmaceutical science &
Technology CFU
Biomarkers & Personalized
Medecine CFU
Scientific & Operational Clinical
Support CFU
Neuroscience PCU
Oncology PCU
Morphotek PCU
Frontier PCU
Collaboration
Next Generation Systems CFU
KAN PCU
Biopharmaceutical Assessments
CFU
Japan/Asia Clinical Reasearch
PCU
Global Regulatory Affairs CFU
Chief Product Creation
Officer (CPCO)
Chief Scientific Officer
(CSO)
57
Aims of specific R&D structure
To ensure up-to-date information from all sources.
To decrease time consuming on the research.
To facilitate decision making and enhances R&D
success.
58
Top 25 companies by pipeline size 2011
300
Number of R&D products
250
Number of originated products
200
150
17th
100
50
0
59
Investigator Initiated Studies IIS
Clinical
supplies
Research grants
Funding to
eligible
applicants
Aim : support scientifically compelling and
innovative research
60
http://www.eisaigrants.com/docs/Getting%20Started%20(IIS).pdf
Neurology
9 products
Fycompa
Aricept
Inoveron /
BANZEL / E2080
Phase I
Phase II
Phase III
Approved
•Partial-onset seizures (Additional indication)
•JP/CN/AS Phase III
•Severe Alzheimer’s disease (Additional Indication)
•JP Phase III
• Pediatric Lennox-Gastaut syndrome (Additional Indication)
•US/EU Phase III
AS-3201
•Diabetic neuropathy
•US/EU Phase II/III
Fycompa
•Pediatric partial-onset seizures(Additional Indication)
•US/EU Phase II
61
http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Vascular and Immunological Reaction
6 products
E5501
Phase I
Phase II
Phase III
•Idiopathic thrombocytopenic purpura
•US/EU/AS Phase III
E5564
•Severe sepsis
•JP/US/EU Phase III
E5501
•Thrombocytopenia in chronic liver disease requiring surgery
•US Phase II
E6201
E6005
Approved
•Psoriasis
•US/EU Phase II
•Atopic dermatitis
•JP Phase II
62
http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Gastrointestinal and Hepatic Disorders
Phase I
Pariet
Pariet
Phase II
Phase III
Approved
• Prevention of recurrence of gastric and duodenal ulcers during
treatment with low-dosage aspirin – ADDITIONAL INDICATION
• JP Phase II/III
•Functional dyspepsia – ADDITIONAL INDICATION
•JP Phase II
63
http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Oncology and Supportive Care
21 Products
8 for an Additional Indication
6 products in phase 3
14 products in phase 2
1 product in phase 1/2
64
http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Oncology and Supportive Care
Phase I
E7040
Halaven
MORAb-003
MORAb-003
MORAb-004
E7080
Phase II
Phase III
Approved
• Transcatheter arterial embolization of hypervascular tumors
• JP Phase III
• Second-line treatment for breast cancer – Non small cell lung cancer - Sarcoma
•JP/US/EU/AS Phase III
•Approved in Japan (april 2011) & Switzerland (may 2011)
• Platinum-sensitive ovarian cancer
•JP/US/EU/AS Phase III
•Non-small cell lung cancer
•US/EU Phase II
• Melanoma – Colorectal cancer - Sarcoma
• US/EU Phase II
• Endometrial cancer – Melanoma – Glioma – Non-small cell lung cancer
65
• US/EU Phase II
http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Innovation
HALAVEN
7 Major NMEs
expected to be
launched
Microtubule dynamics inhibitor
Cancer
LENVATINIB VEGF-R multi target Tyrosine kinase inhibitor Cancer
FARLETUZUMAB IgG1 that targets folate receptor alpha (FRA) Cancer
PERAMPANEL AMPA receptor antagonist
Epilepsy
CLEVUDINE DNA polymerase inhibitor
Hepatitis B
LORCASERIN 5HT2C receptor agonist
Obesity
AVATROMBOPAG Thrombopoietin receptor agonist ITP
66
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Halaven®
1986 : Discovery of Halichondrin B
from marine sponge
1992 : Preclinical studies
(high cytotoxic effects)
1998 : Development of complete synthetic
method by Dr Yoshiro Kishi
2002: National Cancer Institute
started Phases I study
2004: Phase II trials began
2003: Eisai opened additional
Phase I trials
2006: Phase III trial of eribulin
67
Halaven®
EMBRACE Phase III trial
www.halaven.com
Halaven®
EMBRACE Phase III trial
www.halaven.com
Revenue announcement
Revenue by Franchise
(Billion €)
9
LORCASERIN
AVATROMBOPAG
8
Others
7
27%
24%
6
5
GI /
liver
4%
3%
9%
18%
4
Pariet®
Oncology
22%
10%
CLEVUDINE
7%
3
22%
2
Epilepsy, etc.
Neuroscience
38%
1
16%
0
2010
2011
2012
2013
2014
HALAVEN
LENVATINIB
FARLETUZUMAB
PERAMPANEL
Aricept®
2015
71
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Goals
(million €)
Top three epilepsy
player
800
600
400
200
72
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Revenue announcement
Revenue by Franchise
(Billion €)
9
LORCASERIN
AVATROMBOPAG
8
Others
7
27%
24%
6
5
GI /
liver
4%
3%
9%
18%
4
Pariet®
Oncology
22%
10%
CLEVUDINE
7%
3
22%
2
Epilepsy, etc.
Neuroscience
38%
1
16%
0
2010
2011
2012
2013
2014
HALAVEN
LENVATINIB
FARLETUZUMAB
PERAMPANEL
Aricept®
2015
73
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
Goals
Top 3 position in
women’s Oncology
Top 10 Oncology
Player
10/01/2013 : « Farletuzumab did
not meet the study’s primary
endpoint »
74
http://www.morphotek.com/news-events/News-Archive/2013-News/Morphotek-Announces-Top-Line-Results-of-A-Phase-II.aspx
Development of disease modifiers
Phase I for Alzheimer disease
http://www.eisai.com/pdf/eir/emat/4523_110304e.pdf
75
Financial analysis
76
Net sales
Billion €
Net sales (billions of euros)
9
8
7
6
5
4
Net sales (billions of euros)
3
2
1
0
Exchange rate at 12 November 2012 : 1 euro = 100.982 ¥
77
Annual report 2012
Net sales
0,49 b €
0,39 b €
0,44 billions €
Net sales 2010
Japon (44,53 %)
North America (38,51 %)
3,47 billions €
Europe (5,65 %)
ASEAN (5 %)
3 billions €
Others (6,29 %)
Net sales 2011
0,4 b €
0,41 b €
0,42 billions €
Japon (58,73 %)
North America (23,08 %)
1,56 billions €
3,97 billions €
Europe (6,21 %)
ASEAN (6,06 %)
Others (5,92 %)
Exchange rate at 12 November 2012 : 1 euro = 100.982 ¥
78
Annual report 2012
Gross Profit
Million €
9
8
7
6
5
Net sales
4
Cost of sales
Gross profit
3
2
1
0
2008
2009
2010
Exchange rate at 12 November 2012 : 1 euro = 100.982 ¥
2011
79
Net income VS R&D
Million €
2500
2000
1500
1000
500
Acquisition U.S.
biopharmaceutical
company Morphotek &
MGI PHARMA, INC
Net income
R&D expenses
0
-500
Exchange rate at 12 November 2012 : 1 euro = 100.982 ¥
80
ROA (%)
10
8
6
4
2
0
TorreyPines
Therapeutics
Inc.
ROA (%)
-2
-4
81
ROE (%)
20
15
10
ROE (%)
5
0
-5
Return of equity : Which measures how effectively a compagny is able to produce a
profit with the money invested by shareholders
82
Shareholder’s equity
Billion €
Equity
6
5
4
3
2
1
0
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
83
Dividends
84
Foreign tax credits and dividends of foreign
branches
Foreigners credit paid directly by
a Japanese company on income
gained out of the nation.
Credits taxes specially reduced in
a country in the term of fiscal
agreement.
Exclusion of foreign dividend.
http://www.jetro.go.jp/fr/invest/setting_up/laws/section3/page9.html
85
Top 10 Shareholders*
(as of March 31, 2012)
86
Share Price
Tokyo stock Price IndeX
87
EBITDA
Billion € 1.8
- 6,8%
1.6
- 8,6%
- 8,0%
6,4%
1.4
1.2
1
Expected EBITDA
Published EBITDA
0.8
0.6
- 2,6%
0.4
0.2
0
2007
2008
2009
2010
2011
2012
2013
2014
2015
88
SWOT - Strengths
Contributing to a variety of patients in the
Neuroscience area
Multiple approaches for Cancer treatments
Acquisition of MGI Pharma strengthning Eisai’s presence in
growing US oncology market
Consumer oriented approach to Product improvement and
information provision
Eisai’s Key product patent
89
SWOT - Weaknesses
Several « Dramatic Lead Plans »
Setbacks in obtaining regulatory approvals limiting drug
candidates’ commercial potential
90
SWOT - Opportunities
Enhancing footprint in European and emerging markets could
help Eisai offset sales decline in US
Integrating Morphotek R&D capabilities could bring potential
biologics to Eisai
New solutions, developing drug uickly and getting them to the
market
Belviq®
91
SWOT - Threats
Healthcare reforms in Japan could affect Eisai’s domestic
sales growth
Mature product portfolio facing generic erosion
Patent expiration of key drivers products
Globalization with intensified market competition
92
Thank you for your attention
93